(Q85055465)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Distinct immune responses of recombinant plasmid DNA replicon vaccines expressing two types of antigens with or without signal sequences (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Yun-Zhou Yu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Na Li

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Wen-Bin Wang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Shuang Wang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Yao Ma

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Wei-Yuan Yu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Zhi-Wei Sun

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

18 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

7529-7535

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

Gene-based vaccines: recent technical and clinical advances

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

DNA vaccines and their applications in veterinary practice: current perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Current progress of DNA vaccine studies in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

DNA vaccines: recent developments and future possibilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

DNA and RNA-based vaccines: principles, progress and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Increased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Enhancing immune responses using suicidal DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Differential induction of immunoglobulin G subclasses by immunization with DNA vectors containing or lacking a signal sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Enhancement of antibody responses by DNA immunization using expression vectors mediating efficient antigen secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Potentiation of an anthrax DNA vaccine with electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.107

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.08.107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20854897%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference